Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that The United States Food and Drug Administration (US FDA) inspected Unit VI - B, a Formulation manufacturing facility of the Company, situated at Chitkul Village, Patancheru Mandal, Sangareddy District, Telangana, from September 22 to September 29, 2023. At the end of the inspection, a ‘Form 483’ was issued with 1 observation which is procedural in nature. The company will respond to the US FDA within the stipulated timelines and work closely with US FDA to close the observation at the earliest. The company will keep the stock exchanges further informed if there is any material information relating to the above in the future.
